
5,108 Shares in Roche Holding AG $RHHBY Purchased by Enterprise Financial Services Corp

Enterprise Financial Services Corp acquired 5,108 shares of Roche Holding AG, valued at $208,000, during Q2. Other institutional investors also increased their holdings. Analysts have mixed ratings on Roche, with some upgrading to 'Buy' or 'Strong Buy' and others downgrading. Roche's stock opened at $49.01, nearing its 1-year high. The company operates in pharmaceuticals and diagnostics globally.
Enterprise Financial Services Corp purchased a new position in Roche Holding AG (OTCMKTS:RHHBY - Free Report) during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 5,108 shares of the company's stock, valued at approximately $208,000.
- 3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.
A number of other institutional investors also recently bought and sold shares of RHHBY. Boston Common Asset Management LLC boosted its holdings in shares of Roche by 11.1% in the 2nd quarter. Boston Common Asset Management LLC now owns 361,833 shares of the company's stock valued at $14,682,000 after acquiring an additional 36,101 shares during the last quarter. OLD National Bancorp IN lifted its position in Roche by 2.9% during the second quarter. OLD National Bancorp IN now owns 261,317 shares of the company's stock valued at $10,604,000 after purchasing an additional 7,326 shares during the period. Rhumbline Advisers boosted its holdings in Roche by 1.1% in the second quarter. Rhumbline Advisers now owns 108,480 shares of the company's stock valued at $4,422,000 after purchasing an additional 1,228 shares during the last quarter. Yousif Capital Management LLC grew its position in Roche by 7.8% during the 2nd quarter. Yousif Capital Management LLC now owns 88,547 shares of the company's stock worth $3,593,000 after purchasing an additional 6,395 shares during the period. Finally, S&CO Inc. raised its stake in shares of Roche by 4.1% during the 1st quarter. S&CO Inc. now owns 51,199 shares of the company's stock valued at $2,101,000 after buying an additional 2,014 shares during the last quarter.
Analysts Set New Price Targets
Several analysts recently commented on the company. Morgan Stanley reaffirmed an "underweight" rating on shares of Roche in a report on Wednesday, October 29th. HSBC upgraded Roche from a "hold" rating to a "buy" rating and set a $50.00 price objective on the stock in a research report on Thursday, October 2nd. Deutsche Bank Aktiengesellschaft raised shares of Roche from a "sell" rating to a "hold" rating in a report on Tuesday, November 11th. Hsbc Global Res raised shares of Roche from a "hold" rating to a "strong-buy" rating in a report on Thursday, October 2nd. Finally, Jefferies Financial Group lowered shares of Roche from a "hold" rating to a "moderate sell" rating in a research report on Monday, October 27th. Three analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $50.00.
- Viking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval?
Get Our Latest Analysis on RHHBY
Roche Stock Up 2.3%
Shares of RHHBY stock opened at $49.01 on Friday. Roche Holding AG has a 1-year low of $34.10 and a 1-year high of $49.20. The stock has a 50 day simple moving average of $43.38 and a 200-day simple moving average of $41.31.
About Roche
(Free Report)- NVIDIA Invested in These 2 AI Stocks, Should You?
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.
Featured Articles
- Five stocks we like better than Roche
- Expert Stock Trading Psychology Tips
- MP Materials Stock Soared After Earnings—Here’s the Real Reason
- Stock Sentiment Analysis: How it Works
- Why Palantir Slide May Be a Setup for a Long-Term Opportunity
- What Are Dividend Contenders? Investing in Dividend Contenders
- Attention Income Investors: This REIT Is on Sale
Want to see what other hedge funds are holding RHHBY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roche Holding AG (OTCMKTS:RHHBY - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Roche Right Now?
Before you consider Roche, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roche wasn't on the list.
While Roche currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here

